Company Overview and News
Since the correction started in early February we have had dozens of headlines that caused volatility in the equity markets to spike. We’ve had panics over spiking interest rates, the threat of tariff wars, social media data breaches and more recently the potential of airstrikes in the Middle East.
Since early February, the stock market has been on a downhill slide. The trigger was an overheated jobs report on April 2. But since then, it has been a slew of headlines mostly from the White House threatening global growth that have exacerbated the situation.
Twitter Inc (NYSE:TWTR) fell 12% on Tuesday when a nasty headline broke out from Citron Research. This makes it a correction of more than 20% since the recent high.
We all know that the equity markets just got rocked hard recently. After their violent bounce off the Feb. 9 lows, stocks fell into an abyss especially last week. But throughout, the surprising part to me was how well Amazon.com, Inc. (NASDAQ:AMZN) held up, and therein lies my opportunity.
Volatility has lingered in the equity markets since the beginning of February, as a deluge of negative headlines worry investors. Alibaba Group (NYSE:BABA) corrected almost 20%, but within a month Alibaba stock had recovered most of it.
Overstock.com Inc (NASDAQ:OSTK) reported earnings last night, and it was ugly. So understandably investors are punishing the stock by selling it down 15% this morning. This move erases much of the rally that the stock has enjoyed since last October.
While the headlines flying out of the White House are causing havoc in the stock market, United Continental Holdings Inc (NYSE:UAL) staff just created their own nasty headline that is likely to impact its stock for the near-term.
Dollar Tree, Inc. (NASDAQ:DLTR) reported earnings and Wall Street hated it. The stock is down as much as 14% on the headline. Management missed on several accounts, so the punishment is appropriate in nature, but perhaps over done in size. And therein lies my opportunity with DLTR stock.
Target Corporation (NYSE:TGT) reported earnings and Wall Street didn’t like what they saw. Even though the company beat on the top line, they missed their earnings estimate. Under normal circumstances a penny miss wouldn’t be a big deal. However, in this case, TGT stock is known to be one that guides conservatively, which makes this miss even more disappointing than just one penny.
Fitbit Inc (NYSE:FIT) reported earnings last night and the market hated it. They missed on expectations and slashed forward guidance so now the stock has but a sliver of its IPO valuation and capitalization. The knee-jerk reaction on the headline was down 18%. So it’s going to zero…
In Warren Buffett's 2017 annual letter to shareholders, released on Saturday, he discussed the ten-year bet he made in 2007 that an unmanaged, low-cost S&P 500 index fund would outperform an actively managed group of high-cost hedge funds over a ten-year period from 2008 to 2017, when performance is measured on a basis net of fees, costs, and all expenses. See posts here, here and here for past coverage of Buffett's famous bet.
First Solar, Inc. (NASDAQ:FSLR) reported earnings and the stock is consequently down 7% on the headline. This is an opportunity to go long for the mid-term. The macroeconomic picture remains favorable to stock market bulls and the solar industry, including First Solar stock, is an important part of it.
Roku Inc (NASDAQ:ROKU) reported earnings last night and traders hated it — the stock is down massively. So it is safe to say that even though they beat forecasts, they were not in line with expectations. So today’s trade is clearly a case of catching a falling guillotine and not an ordinary knife.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...